Downloaded from http://heart.bmj.com/ on March 10, 2015 - Published by group.bmj.com
Heart Online First, published on February 20, 2015 as 10.1136/heartjnl-2014-306801 Valvular heart disease
ORIGINAL ARTICLE
Additional tricuspid annuloplasty in mitral valve surgery results in better clinical outcome Pieter De Meester,1 Dries De Cock,1 Alexander Van De Bruaene,1 Charlien Gabriels,1 Roselien Buys,2 Frederik Helsen,1 Jens-Uwe Voigt,1 Paul Herijgers,3 Marie-Christine Herregods,1 Werner Budts1 1
Department of Cardiology, University Hospitals Leuven, Leuven, Belgium 2 Department of Rehabilitation Sciences, Catholic University of Leuven, Leuven, Belgium 3 Department of Cardiac Surgery, University Hospitals Leuven, Leuven, Belgium Correspondence to Professor Werner Budts, Congenital and Structural Cardiology, University Hospitals Leuven, Herestraat 49, Leuven B-3000, Belgium; [email protected] Received 12 September 2014 Revised 25 January 2015 Accepted 29 January 2015
ABSTRACT Objective The clinical benefit of tricuspid annuloplasty (TA) in patients undergoing mitral valve surgery (MVS) is still debated. We evaluated the immediate surgical success, postoperative outcome and the medium-term effect of TA in MVS. Methods Patients were included between September 2003 and December 2009 and followed until September 2013 to achieve a median follow-up time of 5 years (IQR 3.7–6.9). The end point of mortality due to cardiac causes and combined end point of cardiac mortality or hospitalisation for heart failure were evaluated. Propensity score adjusted Cox regression was used to evaluate the clinical benefit of TA at the time of MVS. Results Of 150 patients (84 female; 67±12 years), 82 presented with tricuspid regurgitation (TR)
Heart Online First, published on February 20, 2015 as 10.1136/heartjnl-2014-306801 Valvular heart disease
ORIGINAL ARTICLE
Additional tricuspid annuloplasty in mitral valve surgery results in better clinical outcome Pieter De Meester,1 Dries De Cock,1 Alexander Van De Bruaene,1 Charlien Gabriels,1 Roselien Buys,2 Frederik Helsen,1 Jens-Uwe Voigt,1 Paul Herijgers,3 Marie-Christine Herregods,1 Werner Budts1 1
Department of Cardiology, University Hospitals Leuven, Leuven, Belgium 2 Department of Rehabilitation Sciences, Catholic University of Leuven, Leuven, Belgium 3 Department of Cardiac Surgery, University Hospitals Leuven, Leuven, Belgium Correspondence to Professor Werner Budts, Congenital and Structural Cardiology, University Hospitals Leuven, Herestraat 49, Leuven B-3000, Belgium; [email protected] Received 12 September 2014 Revised 25 January 2015 Accepted 29 January 2015
ABSTRACT Objective The clinical benefit of tricuspid annuloplasty (TA) in patients undergoing mitral valve surgery (MVS) is still debated. We evaluated the immediate surgical success, postoperative outcome and the medium-term effect of TA in MVS. Methods Patients were included between September 2003 and December 2009 and followed until September 2013 to achieve a median follow-up time of 5 years (IQR 3.7–6.9). The end point of mortality due to cardiac causes and combined end point of cardiac mortality or hospitalisation for heart failure were evaluated. Propensity score adjusted Cox regression was used to evaluate the clinical benefit of TA at the time of MVS. Results Of 150 patients (84 female; 67±12 years), 82 presented with tricuspid regurgitation (TR)
